In 2013, Calimmune announced they had treated the first patient in a clinical trial involving the use of an innovative gene-based stem cell therapy to help protect individuals infected with HIV from the effects of the AIDS virus. Calimmune CEO Louis Breton spoke to the governing board of California's Stem Cell Agency (CIRM) about the trial. Chief Scientific Officer, Geoff Symonds, PhD detailed the clinical trial procedure, which CIRM is helping fund through a CIRM Disease Team grant. (#25915)